Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus AQUAPHYLLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus AQUAPHYLLIN.
AEROLATE III vs AQUAPHYLLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal: 90-95% unchanged; biliary/fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator